as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,950.6
Change
-1.5 (-0.08%)
Open
₹1,958.7
Prev. Close
₹1,952.1
Day High
₹1,976.9
Day Low
₹1,931.5
Volume Analysis
Traded
32,384
Delivered
16,802
Delivery %
51.88%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (20.1%)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (18.3%)
- •Strong 3-year revenue growth (15.4%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,019.9 | ₹1,998.4 | ₹1,974.5 | ₹1,953.0 | ₹1,929.1 | ₹1,907.6 | ₹1,883.7 |
| Fibonacci | ₹1,998.4 | ₹1,981.06 | ₹1,970.34 | ₹1,953.0 | ₹1,935.66 | ₹1,924.94 | ₹1,907.6 |
| Camarilla | ₹1,963.09 | ₹1,958.92 | ₹1,954.76 | ₹1,953.0 | ₹1,946.44 | ₹1,942.28 | ₹1,938.12 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+39.15%
1 Week
-2.92%
1 Month
+4.34%
3 Months
+6.24%
6 Months
+22.67%
1 Year
+51.89%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹535.11
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.59%
Net margin 10.52% × asset turnover 0.97x × equity multiplier 1.92x
Company Overview
Sector
Healthcare
Market Cap
₹37,595 Cr
P/E (TTM)
36.5
ROE
20.1%
Book Value
₹261.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Emcure Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (99/100), while Valuation (14/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.1%); strong operating margin (20.0%). Strong 3-year EPS growth (18.3%).
TopFund Score — Fundamentals Quality
68/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 7.59 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
AGM approved Berjis Desai’s retirement and reappointments of Mukund Gurjar, Satish Mehta, plus Raghu Kumar’s appointment.
45th AGM voting results: members approved final dividend, director reappointments and key appointments on Sept. 21, 2026.
45th AGM held; shareholders approved Rs 3.60 final dividend and reappointments, while Chairman Berjis Desai steps down.
Allotment of 11,400 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013
Emcure dispatches 45th AGM notice and FY2025-26 annual report; AGM on September 21, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,556 | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Expenses + | 1,261 | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 |
| Operating Profit | 296 | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 |
| OPM % | 19.0% | 20.0% | 18.0% | 18.0% | 19.0% | 19.0% | 18.0% | 19.0% | 20.0% | 21.0% | 21.0% | 19.0% | 21.0% |
| Other Income + | 15 | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 |
| Interest | 52 | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 |
| Profit before tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 |
| Tax % | 26.0% | 26.0% | 30.0% | 27.0% | 26.0% | 26.0% | 32.0% | 24.0% | 26.0% | 26.0% | 26.0% | 29.0% | 26.0% |
| Net Profit + | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| EPS in Rs | 7 | 8 | 6 | 6 | 8 | 10 | 8 | 10 | 11 | 13 | 12 | 13 | 16 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 | 9,683 |
| Expenses + | 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,427 | 7,458 | 7,703 |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,746 | 1,980 |
| OPM % | 16.0% | 14.0% | 24.0% | 23.0% | 20.0% | 18.0% | 19.0% | 19.0% | 20.0% |
| Other Income + | 72 | -25 | -159 | 63 | 39 | 47 | 62 | 100 | -17 |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 | 176 | 144 | 148 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 384 | 415 | 425 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 | 971 | 1,287 | 1,390 |
| Tax % | 37.0% | 4.0% | 36.0% | 28.0% | 25.0% | 27.0% | 27.0% | 27.0% | — |
| Net Profit + | 209 | 101 | 419 | 703 | 562 | 528 | 707 | 941 | 1,019 |
| EPS in Rs | 11 | 5 | 23 | 37 | 29 | 28 | 36 | 49 | 53 |
| Dividend Payout % | 32.0% | 54.0% | 4.0% | 8.0% | 7.0% | 7.0% | 8.0% | 7.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 | 4,760 |
| Borrowings + | 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | 1,023 | 1,521 |
| Other Liabilities + | 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | 2,653 | 3,043 |
| Total Liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 |
| Fixed Assets + | 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 | 3,319 |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 | 177 | 273 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 | 95 | 20 |
| Other Assets + | 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | 4,652 | 5,903 |
| Total Assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 |
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 | 190 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 444 | 500 | 704 | 768 | 747 | 1,097 | 852 | 944 |
| Cash from Investing Activity + | -409 | -168 | -256 | -574 | -468 | -715 | -96 | -1,175 |
| Cash from Financing Activity + | -735 | -301 | -189 | -152 | -145 | -164 | -814 | 343 |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 | 112 |
| CFO/OP | 77 | 84 | 74 | 81 | 80 | 107 | 75 | 75 |
| Free Cash Flow | 39 | 362 | 571 | 349 | 345 | 801 | 475 | 400 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Public | 15.05% | 15.15% | 15.58% | 16.39% | 14.46% | 12.43% | 12.69% | 8.84% |
| Promoters | 78.08% | 77.94% | 77.92% | 77.92% | 77.88% | 77.87% | 77.87% | 77.83% |
| FII | 2.91% | 3.05% | 3.06% | 2.86% | 3.29% | 3.59% | 3.35% | 4.87% |
| DII | 3.96% | 3.87% | 3.44% | 2.84% | 4.36% | 6.1% | 6.1% | 8.46% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Emcure Pharmaceuticals L (this stock) | 37,595 | 36.5 | 7.59 | 20.1% |
| Narayana Hrudayalaya Ltd. | 38,040 | 44.1 | 8.38 | 20.5% |
| Wockhardt Limited | 36,814 | 92.3 | 7.45 | 6.11% |
| Global Health Limited | 40,516 | 70.8 | 10.24 | 15.2% |
| Sai Life Sciences Limited | 33,821 | 92.0 | 13.61 | 15.4% |
| Krishna Inst Of Med Sci L | 32,765 | 157.0 | 13.88 | 11.3% |
| Dr. Lal Path Labs Ltd. | 32,299 | 57.4 | 12.83 | 22.3% |
Which Mutual Funds Hold Emcure Pharmaceuticals L?
Frequently Asked Questions about Emcure Pharmaceuticals L
Emcure Pharmaceuticals L (EMCURE) closed at ₹1,950.6 on NSE on 25 September 2026, down 1.5 (0.08%) from the previous close.
Emcure Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol EMCURE.
Emcure Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 36.5.
Emcure Pharmaceuticals L has a dividend yield of 0.18%.
Emcure Pharmaceuticals L's 52-week high is ₹2,101.0 and its 52-week low is ₹1,260.0.
Emcure Pharmaceuticals L has a market capitalisation of ₹37,595 crore.
Emcure Pharmaceuticals L has a TopFund Quality Score of 68/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Emcure Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.